Seraph 100 is the first device with an indication to specifically reduce pathogens in the bloodstream in adjunction to antibiotic therapy. An effective long-awaited approved adjunctive therapy to conventional regiments for both drug-resistant and drug-susceptible pathogens
An EU clinical safety trial showed no device or treatment-related adverse or serious adverse events. Multiple, independent pre-clinical experiments have shown the safety and biocompatibility of the Seraph 100. Rapid reduction of pathogens requires as little as one 4-hour session, and can be used as an early intervention prior to pathogen identification due to its broad-spectrum binding
The binding properties of the filter allow Seraph 100 to reduce drug-resistant pathogens, without the threat of pathogens becoming resistant in the future
ExThera’s proprietary Seraph 100Microbind Affinity Blood Filter (Seraph 100) is the first CE-certified technology designed to reduce blood-borne pathogens during bloodstream infections.
The Seraph 100 is both fast and efficient. The device is engineered to operate with a low pressure drop at blood flow rates up to 350 mL/ minute and is designed to easily “add-on” to common blood purification equipment.
ExThera Medical was established in 2007 by the Emergence Venture Partners life science incubator and ExThera AB at Karolinska Institute in Stockholm. We focus on the treatment of drug-resistant and drug-sensitive blood infections in high-risk patient populations, and provide field-deployable versions for the biological defense and military fields. Our headquarters is in Martinez, California.More about ExThera Medical
MARTINEZ, Calif. – PURIFY OBS, an observational study of critically-ill COVID patients...
MARTINEZ, Calif. – Critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood...